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Non-neoplastic epithelial lesions of the vulva (NNEDV) lichen sclerosus (LS) and squamous hyperplasia (SH) have been implicated in
the pathogenesis of squamous cell carcinoma of the vulva (SCC). To date, there have been no recognisable precursor lesions for
SCC associated with NNEDV. TP53 is the most frequent genetic change in human cancers and can indicate both aetiology and
molecular pathogenesis of tumours. A total of 27 SCC patients underwent immunohistochemistry (IHC) and TP53 mutational
analysis using microdissection and direct sequencing. There were 19 patients with areas of adjacent epidermis: 17 had NNEDV (four
SCCs had more than one adjacent lesion) and two had normal epidermis. In all, 70.4% of the SCCs, 40% LS and 22.2% SH
demonstrated overexpression of p53. In total, 77.8% of SCCs, 46.7% of LS and 22.2% SH demonstrated mutations in TP53, with the
majority of lesions having a mutation in codon 136. Eight cases were identified where the same mutation was identified in the SCC
and in the adjacent area. These data suggest that TP53 mutations develop in NNEDV and are intrinsic to the clonal evolution that
leads to SCC. The type of mutation detected is more likely to occur due to endogenous cellular changes rather than exogenous
carcinogen exposure.
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Lichen sclerosus (LS) is an inflammatory disease of unknown
aetiology and pathogenesis. It is a disorder of the skin, which is
most common in the genital area but can occur anywhere on the
body. It affects both sexes and all age groups. In a review by
Meffert et al (1995) of 5207 patients, the female-to-male incidence
was reported as 6:1, with genital involvement in 83% of cases. The
majority of sufferers of anogenital LS are either middle-aged or
elderly women. The predominant symptom in females is an
intractable itch, which is often associated with dysuria, dyspar-
eunia, dryness of the skin, labial stenosis or fusion and, in
children, constipation (Laude et al, 1980).
There have been many studies assessing the risk of squamous
cell carcinoma of the vulva (SCC) in inflammatory diseases of the
vulva. Wallace (1971) reported that 12 of 290 (4%) patients
developed SCC following a history of LS during a 12-year period
but further follow-up studies have shown a wide range of risk of
progression (Hart et al, 1975; Meffert et al, 1995; Carlson et al,
1998). Others (Rueda et al, 1994; Scurry et al, 1997; Vilmer et al,
2000) have looked at the skin adjacent to SCC which, not
uncommonly, shows epithelial disorders; the most common are
LS and squamous hyperplasia (SH).
The TP53 gene is located on chromosome 17p13.1; it consists of
11 exons with 10 introns. Exon 1 is noncoding, while exons 5–8
are part of the highly evolutionarily conserved domain. Mutations
in the TP53 gene are the most frequent genetic changes in human
cancers, and the spectrum of mutations can indicate tumour
aetiology and molecular pathogenesis (Levine et al, 1991; Green-
blatt et al, 1994). In addition, a comparison of the mutation profile
between malignant and potential premalignant lesions can give an
indication of the clonality and progression of such tumours.
The aim of this study was to assess the presence of TP53
mutations in SCC and the adjacent non-neoplastic epithelial
disorders of the vulva (LS and SH; NNEDV) and to compare the
results of the mutation analysis with immunohistochemsitry (IHC)
results. It was hoped that the data would also provide information
on the clonality of SCC and the carcinogenic progression of
adjacent lesions.
MATERIALS AND METHODS
Sample details
A total of 27 formalin-fixed, paraffin wax-embedded vulvectomy
specimens from the files of the Histopathology Departments of the
Royal Free and University College Medical School (Royal Free and
Gower Street Campuses) were used with a mean age of 71.678.6
years (range 49–86 years). Nineteen patients also had adjacent
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yepidermis available for microdissection; 17 of these had an
NNEDV (LS and/or SH) with a total of 24 NNEDV specimens
and two had normal epidermis adjacent to the SCC.
Immunohistochemical analysis
Sections (4mm) were cut for immunohistochemical analysis and
histopathological confirmation of diagnosis by two pathologists
(EB, JCC).
The IHC procedure has been described previously (Rolfe et al,
2001, 2002). Briefly, sections were dewaxed in xylene and
rehydrated through different grades of ethanol up to distilled
water. Endogenous peroxidase was blocked by using a 3%
hydrogen peroxide solution. Antigen retrieval was performed by
heating the sections in sodium citrate buffer in a microwave
(2 5min). Nonspecific binding was blocked by preincubation
with 10% normal rabbit serum for 10min at room temperature. A
primary mouse monoclonal antibody, which recognises both wild-
type and mutant p53 (DO-7, Dako, Ely, Cambs, UK) was applied at
1:100 dilution for 1h at room temperature. All stages were carried
out at room temperature with phosphate-buffered saline used for
washing between stages. Following incubation with a secondary
antibody, a standard streptavidin–biotin–horseradish complex
was then used, with 3, 30-diaminobenzidine tetrahydrochloride as
the chromogen to detect the presence of the p53 protein. Slides
were counterstained with Mayers’ haemalum (Merck, Lutterworth,
Leics, UK).
To ensure staining consistency and reproducibility, a number of
precautions were taken: (i) All sections from different blocks were
stained as a batch on the same day and the process was repeated
four times for each protein; and (ii) results were analysed
independently by the three observers (EB, JCC and KJR). In all
cases, there was o5% variation in staining between sections and
observers.
p53 staining was classified as the percentage of positive (brown)
nuclei in specific epidermal areas or as a percentage of tumour
cells with p10% counted as negative and 410% as positive, as
described previously (Rolfe et al, 2002).
Microdissection
Two sections sequential to the IHC stained slides were dewaxed
and rehydrated up to sterile, double-distilled water. Sections were
then stained with toluidine blue (Sigma-Aldrich, Poole, Dorset,
UK) which enabled the various lesions to be easily identified.
Lesions were carefully removed without contamination from
surrounding tissue (Figure 1A, B) using a sterile technique with
a 27-gauge needles (Davies Health Care) and each lesion placed
separately into separate sterile Eppendorf microcentrifuge tubes.
Lesions were flooded with 200ml of digestion buffer (10mM Tris-
HCl, pH 8.5, 1mM EDTA, 0.5% Tween 20
s) containing 1mgml
 1
of proteinase K (Sigma-Aldrich, Poole, Dorset, UK). Samples were
incubated at 371C for 20h and then heated to 951C for 10min to
inactivate the proteinase K. The solution was then centrifuged at
3500 revolutions per minute for 10min and the supernatant
removed, placed in a sterile 1.5ml Eppendorf tube, and stored at
41C.
PCR
PCR was performed using commercially available primers for
exons 5–8 of TP53 (Cruachem, Glasgow, Scotland; Table 1). PCR
was performed using 4ml of the DNA extracted from the paraffin
sections in a 50ml PCR mix of 1.5mM MgCl2, 14–17 pmoles of each
primer, 200mM deoxynucleoside triphosphates (Pharmacia, Milton
Keynes, Bucks, UK), in the PCR buffer (20mM (NH4)2SO4,7 5m M
Tris-HCl, pH 8.8, 0.01% Tween
s) with 2.5U Taq enzyme
(‘Thermus icelandicus’; Advanced Biotechnologies, Epsom, Surrey,
UK). PCR was performed over 35 cycles with an annealing
temperature for the four exons of 601C. PCR products, along with a
negative control (DNA omitted and sterile double-distilled water
used instead) were run on a 10% nondenaturing polyacrylamide
gels to assess for the presence of product and any contamination.
Sequencing
Sequencing was performed commercially from both strands of the
DNA (MWG-Biotech, Milton Keynes, Bucks, UK). Briefly, this
involves reamplification of the product using nested primers,
followed by M13 sub-cloning. Detection was by a Li-Cor infrared
detection system. When a mutation was detected, the PCR and the
sequencing were both repeated to confirm the result.
Statisticss
A P-value of o0.05 was considered to be statistically significant
and w
2 analysis was used.
A
B
Figure 1 (A) A slide stained by IHC showing overexpression of p53 in
the SCC. (B) A toluidine blue-stained adjacent slide demonstrating the area
that had shown overexpression of p53, removed by microdissection.
Table 1 Primers used for TP53 PCR amplification
Exon 5 Forward GGAATTCTGTTCACTTGTGCCCTGACTTTCAAC
Reverse GCAACCAGCCCTGTCGTCTCTCCA
Exon 6 Forward CCAGGCCTCTGATTCCTCACTGATTG
Reverse AGGGCCACTGACAACCACCCTTAAC
Exon 7 Forward CCTGCTTGCCACAGGTCT
Reverse CCGGAAATGTGATGAGAGGT
Exon 8 Forward AGGTAGGACCTGATTTCCTTACTGCC
Reverse GGAATTCTGAGGCATAACTGCACCCTTGGTCT
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p53 IHC
In total, 70.4% (19 out of 27) of SCCs demonstrated overexpression
of p53 (410% nuclear staining). Squamous cell carcinoma of the
vulva showed different patterns of staining depending on the grade
of the tumour with well-differentiated tumours demonstrating
expression around the periphery of the keratin pearls and
moderately to poorly differentiated SCCs demonstrating expres-
sion throughout the tumour (Figure 2). Results are summarised in
Table 2.
None of the normal epidermis adjacent to SCC demonstrated
overexpression of p53. In all, 40% (six out of 15) of the LS
lesions did demonstrate overexpression of the p53 protein, and
staining was confined to the basal/parabasal layers of LS. In all
22.2% (two out of nine) of adjacent SH areas were identified as
overexpressing p53 with staining identified throughout the
epidermis.
There was no statistically significant difference demonstrated
between any of the lesions when using w
2 analysis.
TP53 mutations
In total, 77.8% (21 out of 27) of SCCs demonstrated a TP53
mutation (in codons 136, 213, 214, 234, 235, 248); two SCCs
demonstrated mutations and polymorphisms (exons 244 and 258)
with 19 SCCs demonstrating the same mutation in exon 5 (codon
136:CAA-TAA, Gln-stop; Figure 3) and a further SCC
demonstrating a mutation in the intron between exons 7 and 8.
In all, 46.7% (seven out of 15) of adjacent LS lesions were
identified as containing a mutation in the TP53 gene with all
identified as having the mutation in codon 136; however, one LS
lesion had the mutation in codon 136 with a further mutation
in exon 7 (codon 248:CGG-CAG; Arg-Gln). In all, 22.2%
(two out of 9) of adjacent SH were identified as having a
mutation in the TP53 gene with all (mutant positives) identified
as having the mutation in codon 136 and one SH lesion identified
as having the mutation in codon 136 plus a mutation in exon 7,
codon 248.
Clonality analysis
Eight cases were identified where the same mutation was
identified in the SCC and the adjacent lesion (with a further
adjacent lesion demonstrating the same polymorphism as the
SCC) resulting in 50% (eight out of 16) of our SCCs having an
adjacent lesion with the same clone of cells. When studying
individual lesions, 46.7% (seven out of 15) of adjacent LS lesions
and 33.3% of adjacent SH showed the same clone of cells as the
adjacent SCC.
Correlation between mutation and IHC
In all, 66.7% (14 out of 21) of SCC, which overexpressed p53,
demonstrated a mutation, though p53 overexpression was also
identified in SCCs that showed wild-type TP53 (83.3%). Adjacent
lesions showed correlation with wild-type TP53 and no over-
expression of p53 (Table 3).
Figure 2 Overexpression of p53 in a well-differentiated SCC:
magnification  40.
Table 2 Results of immunohistochemistry and mutational analysis
Lesion Immunohistochemistry Mutation
1 SCC + Exon 5 codon 136
SH + Exon 5 codon 136
LS + Exon 5 codon 136
2 SCC + Exon 5 codon 136
N   Wild type
3 SCC   Exons 5 & 7, codons 136 and 244
4 SCC + Exon 5, codon 136
N   Wild type
5 SCC + Exon 5, codon 136
SH   Wild type
6 SCC   Wild type
SH   Wild type
7 SCC + Wild type
8 SCC + Exon 5, codon 136
LS   Exon 5, codon 136
SH   Wild type
LS
a   Wild type
9 SCC   Exon 5, codon 136
10 SCC + Exon 5, codon 136
LS   Exon 5, codon 136
11 SCC   Exon 5, codon 136
SH   Wild type
LS   Exon 5, codon 136
12 SCC + Exon 5, codon 136
SH   Wild type
13 SCC + Exon 5 & 7, codons 136 & 248
LS + Exon 5 & 7, codons 136 & 248
14 SCC + Wild type
LS + Wild type
15 SCC + Exon 6, codon 213
LS   Wild type
16 SCC + Exon 7, Intron between 7 & 8
17 SCC   Exon 5, codon 136
SH   Exon 5 &7, codons 136 & 248
18 SCC + Exon 5, codon 136
LS   Wild type
19 SCC   Exon 5 & 7, codon 136 & 258
SH   Exon 7, codon 258
20 SCC   Exon 5 & 7, codon 136 & 235
LS   Exon 5, codon 136
21 SCC + Exon 5 & 7, codons 136 & 234
22 SCC   Exon 6, codon 214
LS   Wild type
23 SCC + Exon 5, codon 136
LS + Exon 5, codon 136
24 SCC + Wild type
25 SCC + Exon 5 & 7, codon 136 & 248
26 SCC + Exon 5, codon 136
27 LS
b   Wild type
LS
b + Wild type
SCC + Wild type
LS + Wild type
SH + Wild type
SCC¼squamous cell carcinoma of the vulva; LS¼lichen sclerosus; SH¼squamous
hyperplasia.
aLesion not adjacent to SCC.
bLesions taken at different time.
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Correlation of sequencing and IHC data
There was a correlation (66.7%) between TP53 mutations and p53
protein overexpression in SCC, but positive IHC expression did
not necessarily imply a mutation with 83% of SCCs overexpressing
p53 having wild-type TP53.
The antibody used, DO-7, is known to attach to the amino
terminus of the human p53 protein at amino-acid location 21–25
(Vojtesek et al, 1992; Stephen et al, 1995) and is able to detect the
overexpression of both wild-type and mutant p53. The antibody
detects a stabilised form of the protein that, if not stabilised
through mutation, is stabilised through other means, which results
in an interruption of the degradative pathway of wild-type p53
(Wynford-Thomas, 1992).
TP53 mutations in SCC
In total, 77.8% of the SCCs in this study showed a mutation in the
TP53 gene. It is possible that those SCCs where no TP53 mutation
was identified could have mutations outside exons 5–8 of the TP53
gene, though it has been estimated that less than 5% of mutations
occur outside this highly conserved area.
This work has demonstrated a higher percentage of SCCs with a
TP53 mutation compared with that found by other authors, who
have shown a range of 32–58% (Kim et al, 1996; Sliutz et al, 1997;
Ngan et al, 1999). There are two possible reasons for this
difference: (i) patient details; the majority in this group were
older than the other studies and the majority were associated with
NNEDV; and (ii) technical differences with this study using direct
sequencing and microdissection.
TP53 mutation profile in SCC
The mutation profile in the TP53 gene can indicate the potential
cause of the mutation. Three codons (213, 244 and 248) from this
work were from CpG sites and other authors have shown that such
CpG sites are important regions for mutation in SCC (Milde-
Langosch et al, 1995; Pilotti et al, 1995; Kim et al, 1996; Ngan et al,
1999). Transitions at CpG sites are believed to be caused by
endogenous processes. There are many endogenous processes that
could result in carcinogenesis, and these have in part been
attributed to cell proliferation (Ames and Gold, 1990). Tissue
regeneration after toxicity could increase the frequency of
mutation from replication errors. Other processes, such as
inflammation, oxygen radical damage accompanying tissue injury,
and a flux of macrophages may contribute to the mutation
frequency (Harris et al, 1978).
It is possible that the profound itching and resultant scratching
associated with NNEDV may contribute to the pathogenesis of
associated SCC. It has previously been demonstrated that there is
increased cell proliferation in LS and LS adjacent to SCC (Rolfe
et al, 2001, 2002) and there may therefore be an increased
likelihood of a spontaneous mutation (Hietanen et al, 1995).
Inflammatory processes may also be involved in oxidative damage
caused by free radicals (Carlson et al, 1998). The inflammatory
infiltrate of LS has been shown to possess in excess of 10% of
macrophages (Tsang and Chan, 1992; Carlson et al, 2000), which, if
activated, are capable of producing free radicals that have been
shown to have a mutagenic activity (Weitzman and Stossel, 1981;
Weitberg et al, 1983).
The mutation at codon 136 was demonstrated in half of all
lesions studied, and results in a CAA-TAA, that is, amino-acid
change gln-stop. Up to 1996, there had been 10 reports of
this mutation in sporadic tumours (Hollstein et al, 1996),
including squamous cell carcinoma of the head and neck
(Chung et al, 1993), actinic keratosis (Ziegler et al, 1994) and
other cancers, for example, oesophageal carcinomas (Huang et al,
1993).
TP53 mutations in adjacent lesions
Alterations in the p53 pathway are generally regarded as occurring
prior to invasion of the basement membrane in tumours of the
lung, oesophagus, head and neck, breast and cervix, and as a late
event (i.e. after invasion has occurred) in ovarian cancer. In
ulcerative colitis and other inflammatory conditions, TP53
mutations have been found in the earliest recognised dysplastic
lesions (Burmer et al, 1991, 1992; Yin et al, 1993). This current
work on SCC has indicated that TP53 mutations do appear to be
early events with eight patients showing an identical TP53
genotype in the adjacent lesion as in the SCC. The relatively low
percentage of mutations in SH (22%) could be due to more
contaminating cells being present, for example, inflammatory
cells in the thickened epidermis, even with the use of micro-
dissection. Ren et al (1996) described the epidermis as being
composed of epidermal proliferative units each derived from a
single stem cell. It is these stem cells that probably harbour the
mutations, which are then passed on to the daughter cells. It has
been previously proposed that the stepwise progression of
replacement of normal squamous epidermis by atypical keratino-
cytes does not occur in SCC associated with NNEDV; rather the
atypical features are confined to the basal and parabasal layers.
Hence, SCC arising from LS may arise directly from basal
keratinocytes, which invade the underlying dermis (Carlson et al,
1998).
Clonality in SCC
In total, 50% of patients were identified as showing identical
mutations in the SCC and adjacent lesion. Only one other
study has identified mutations in LS adjacent to SCC and
this was in only one case (Milde-Langosch et al, 1995). In our
work, 46.7% of adjacent LS and 33.3% of SH adjacent to
Figure 3 The TP53 sequence for part of the reverse strand of exon 5.
The R demonstrates a heterozygous mutation in codon 136. This sequence
was produced from LS adjacent to SCC. The green peak indicates an A,
which in wt TP53 is a G (small red peak). This sequence was confirmed by
analysis of the forward strand and repeat PCR and sequencing.
Table 3 Correlation of immunohistochemistry and mutations in each
lesion
Lesion IHC+/mt+ IHC /mt+ IHC+/mt  IHC /mt 
SCC 66.7% (14/21) 33.3% (7/21) 83% (5/6)* 16.7% (1/6)
SH 50% (1/2) 50% (1/2)** 14.3% (1/7) 85.7% (6/7)
LS 42.8% (3/7) 57% (4/7) 37.5% (3/8) 62.5% (5/8)
* Mutation in intron considered wild-type TP53. ** Polymorphism considered wild-
type TP53. IHC¼immounohistochemistry; mt¼mutation; SCC¼squamous cell
carcinoma of the vulva; SH¼squamous hyperplasia; LS¼lichen sclerosus.
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data suggest that TP53 mutations develop in NNEDV and are
intrinsic to the clonal evolution that leads to SCC, as the
multiplicity of TP53 mutational events indicate that identical
mutations are unlikely to occur independently (Greenblatt et al,
1994).
TP53 mutations appear to play an important role in the
pathogenesis of NNEDV to SCC, and those mutations appear to
occur through endogenous processes and NNEDV appear to be
clonal in origin when comparing TP53 mutational analysis.
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